Answers are grounded in this paper and cite their sources.
While the pipeline for new antihypertensive drugs is shrinking, targeting novel pathways like the protective RAAS and dual NEP inhibition provides a glimmer of hope for future therapies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Paulis et al. (2015) conducted a review in Hypertension. Novel antihypertensive agents was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: